AVNR—It’s not clear that the stroke and Alzheimer’s numbers should be counted as part of the addressable market. Just because the FDA label didn’t explicitly restrict use to patients with MS/ALS doesn’t mean that third-party payers won’t (#msg-56113786).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”